Why the study?
Much of what is known about pediatric dyslipidemia has been extrapolated from adult data, warranting a summary of types frequently encountered during childhood and adolescence with a focus on screening, diagnosis, and management.
Screening and pharmacologic management of pediatric dyslipidemia are safe and important for reducing adult ASCVD risk.
May support early pharmacologic intervention in select pediatric dyslipidemia; leaves open need for prospective trials confirming adult ASCVD reduction.
PURPOSE OF REVIEW: To summarize types of dyslipidemia frequently encountered during childhood and adolescence, with a focus on screening, diagnosis, and management. RECENT FINDINGS: It is important that screening for atherosclerotic cardiovascular disease (ASCVD) begin in childhood. Genetic testing allows for increased awareness of dyslipidemia and more targeted intervention. Pharmacologic treatment of pediatric dyslipidemias has a good safety profile and can reduce adult ASCVD risk. SUMMARY: Much of what is known about pediatric dyslipidemia has been extrapolated from adult data, but recently, there have been increasing investigations within the pediatric population to better guide diagnosis and management of these disorders.
No takes yet. Share an insight, caveat, or question.
Yeung et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: